Yttriga
yttrium [90Y] chloride
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for Yttriga. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Yttriga.
Authorisation details
Product details | |
---|---|
Name |
Yttriga
|
Agency product number |
EMEA/H/C/000596
|
Active substance |
yttrium (90Y) chloride
|
International non-proprietary name (INN) or common name |
yttrium [90Y] chloride
|
Therapeutic area (MeSH) |
Radionuclide Imaging
|
Anatomical therapeutic chemical (ATC) code |
V09
|
Publication details | |
---|---|
Marketing-authorisation holder |
Eckert Ziegler Radiopharma GmbH
|
Revision |
10
|
Date of issue of marketing authorisation valid throughout the European Union |
19/01/2006
|
Contact address |
Robert-Rossle-Str. 10
D-13125 Berlin Germany |
Product information
18/12/2020 Yttriga - EMEA/H/C/000596 - N/0018
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Diagnostic radiopharmaceuticals
Therapeutic indication
To be used only for the radiolabelling of carrier molecules, which have been specifically developed and authorised for radiolabelling with this radionuclide.
Radiopharmaceutical precursor - Not intended for direct use in patients.